| I-73 Ioannis Loisios-Konstantinidis Combining physiologically based pharmacokinetic modeling and simulations and allometry to inform the starting dose of asciminib in pediatric patients Wednesday 10:00-11:30 |
| I-79 Belén Pérez Solans Pharmacokinetic analysis across studies to drive knowledge-integration: optimal dose finding of rifampicin for the treatment of drug-susceptible tuberculosis in children Wednesday 10:00-11:30 |
| I-80 Soumya Perinparajah Modelling the pharmacodynamics of rituximab biosimilar in children with rheumatological conditions Wednesday 10:00-11:30 |
| I-81 Anne Ravix Dosing optimization of amoxicillin in children treated for Lyme disease Wednesday 10:00-11:30 |
| I-82 Leyanis Rodriguez Vera Showcasing the potential of PBPK modeling to inform drug-drug interactions specific recommendations for pediatric labeling: omeprazol case example Wednesday 10:00-11:30 |
| I-84 Stephan Schaller Using PBPK Modeling to support an adaptive “First-in-Pediatric” trial design of Sonlicromanol for the treatment of Primary Mitochondrial Disease Wednesday 10:00-11:30 |
| I-85 Maja Skataric Dabrafenib and Trametinib dose optimization in 6-17 year old tumor agnostic patients based on established efficacy surrogate targets in adults Wednesday 10:00-11:30 |
| I-86 Melina Steichert Enalapril orodispersible minitablets for pediatric heart failure - a population pharmacokinetic analysis from multicenter Phase II/III LENA clinical trials Wednesday 10:00-11:30 |
| I-87 Mita Thapar Population pharmacokinetic and exposure-response analysis for ambrisentan for the treatment of pulmonary arterial hypertension in paediatric subjects aged 8 to less than 18 years. Wednesday 10:00-11:30 |
| I-90 Lufina Tsirizani Population pharmacokinetics of ritonavir-boosted darunavir in children aged 3 to 15 years in the CHAPAS 4 trial living with HIV in Africa. Wednesday 10:00-11:30 |
| II-98 Jen-Hao (Eric) Wu Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia – results of study ITCC-059 Wednesday 15:35-17:00 |
| III-05 Fan Cheng Favipiravir pharmacokinetics in immunocompromised infants and children with chronic RNA viral infections Thursday 10:15-11:45 |
| III-06 S. Y. Amy Cheung Predicting RSV prophylaxis in the infant target population – assessing monoclonal antibody versus maternal vaccination efficacy using MBMA Thursday 10:15-11:45 |
| III-07 Marc Codaccioni Predictive performance of two hepatic CYP3A4 ontogeny within a paediatric PBPK model. Thursday 10:15-11:45 |
| III-08 Alessandro Di Deo A model-based algorithm for mycophenolate dose adjustment in paediatric transplantation patients Thursday 10:15-11:45 |
| III-11 Klervi GOLHEN Characterizing effect of methotrexate on adalimumab PK in pediatric patients with inflammatory rheumatic disease Thursday 10:15-11:45 |
| III-12 Silvia Grandoni Efficacy extrapolation and dose rationale for duloxetine in paediatric chronic pain Thursday 10:15-11:45 |
| III-21 Feras Khalil A joint parent-metabolite model to characterize the pharmacokinetic profile of tapentadol and its metabolites in the pediatric population and inform a model-based evaluation of a post-approval commitment pediatric trial Thursday 10:15-11:45 |
| III-34 Xia Li Model Informed Dose Evaluation for Aticaprant in Adolescent Patients Following the Adult Dose Regimen Thursday 10:15-11:45 |
| III-91 Anne van Rongen Quantification of renal drug clearance in neonates born Small for Gestational Age (SGA) compared to neonates born Appropriate for Gestational Age (AGA) Thursday 10:15-11:45 |
| III-93 Yunjiao Wu When will the glomerular filtration rate in preterm neonates catch up to their term peers? Thursday 10:15-11:45 |
